NCT00831675View on ClinicalTrials.gov

Study of Safety and Immunogenicity of Fluzone® in Healthy Children

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 2004

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions
Influenza
Interventions
BIOLOGICAL

Influenza Vaccine 2004-2005 Paediatric Formulation

0.25 mL (Day 0 and Day 28), Intramuscular

BIOLOGICAL

Influenza Vaccine 2004-2005 Paediatric Formulation

0.25 mL (Day 0 and Day 28), Intramuscular

Trial Locations (1)

23510

Norfolk

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00831675 - Study of Safety and Immunogenicity of Fluzone® in Healthy Children | Biotech Hunter | Biotech Hunter